Equity Screeners to view more equity screening toolsThe Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also
D Pharm Retained Earnings AnalysisRetained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Beginning RE + Income
|D Pharm||Retained Earnings||=|
About Retained EarningsRetained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.Compare to competition
Based on latest financial disclosure D Pharm LTD has Retained Earnings of -5.39E8. This is 157.87% lower than that of the Healthcare sector, and 656.28% lower than that of Biotechnology industry, The Retained Earnings for all stocks is 105.78% higher than the company.
D Pharm LTD Fundamental Drivers Relationships
D Pharm LTD is rated # 4 in beta category among related companies. It is rated # 3 in price to sales category among related companies .
|Price to Sales ( times )|
D Pharm Earnings Per Share Peer Comparison
D Pharm is currently under evaluation in earnings per share category among related companies.
D Pharm current financial ratios
|Return On Equity||(400.00)%|
|Return On Asset||(42.09)%|
|Price to Sales||37.00X|
|Cash and Equivalents||314K|
|Cash per Share||0.05X|
|Debt to Equity||45.70%|
|Book Value Per Share||0.11X|
|Cash Flow from Operations||(313K)|
|Earnings Per Share||(0.14)X|
|Number of Employees||11|